Shelby Brooks, APRN
Nurse Practitioner · Topeka, KSNPI 1912561739
Payments from drug & device makers
Across 182 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$869
- Regeneron Healthcare Solutions, Inc.$619
- GSK$497
- Amgen$368
- Sanofi$280
- Novartis$176
- plus $949 from 19 others
What the payments were for
- Food & beverage$3,32388%
- Education$43412%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 41 | $869 |
| Regeneron Healthcare Solutions, Inc. | 24 | $619 |
| GSK | 25 | $497 |
| Amgen | 21 | $368 |
| Sanofi | 18 | $280 |
| Novartis | 9 | $176 |
| Sanofi-aventis U.S. LLC | 2 | $160 |
| Optinose US, Inc. | 4 | $92 |
| Kaleo, Inc. | 5 | $88 |
| Biocryst US Sales Co., LLC | 5 | $82 |
| Genentech USA, Inc. | 3 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $65 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $54 |
| Integra Lifesciences Corporation | 3 | $53 |
| Greer Laboratories, Inc. | 2 | $44 |
| Vertex | 2 | $43 |
| Neos Therapeutics, LP | 2 | $37 |
| Merck | 2 | $34 |
| Convatec Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $20 |
| Cochlear Americas | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $17 |
| Medtronic | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$3,757 in reported general payments places this provider in the 90th percentile of 1,326 nurse practitioner providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $38,281 |
| Breo ElliptaFluticasone/Vilanterol | 54 | $28,297 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $21,037 |
| Epinephrine | 105 | $20,272 |
| Advair HfaFluticasone Propion/Salmeterol | 43 | $18,972 |
| Arnuity ElliptaFluticasone Furoate | 49 | $15,391 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $14,578 |
| Fluticasone Propionate HfaFluticasone Propionate | 26 | $9,820 |
| DuleraMometasone/Formoterol | 22 | $9,659 |
| Spiriva RespimatTiotropium Bromide | 15 | $8,105 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 61 | $5,913 |
| BreynaBudesonide/Formoterol Fumarate | 34 | $5,492 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $4,874 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $4,353 |
| Montelukast Sodium | 359 | $2,420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $497 | $86,843167 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $869 | $35,61580 claims |
| Hikma Pharmaceuticals USAEpinephrine | $15 | $20,272105 claims |
| MerckDulera | $34 | $9,65922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,326 nurse practitioner providers in Kansas.
Other nurse practitioner in Topeka
- Gary GrafTopeka$726K
- Shannon GreggTopeka$140K
- Kelli BradburyTopeka$20K
- Laura WelbornTopeka$8K
- Alexandra HeerenTopeka$8K
- Amie WunderTopeka$8K
- Jayda RuppTopeka$7K
- Lora UtechTopeka$6K
- Sarah FitzmauriceKansas City$247K
- Anna ShortRoeland Park$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.